Structure Therapeutics Appoints New CMO and CDO

TL;DR

Structure Therapeutics beefs up leadership with new CMO & CDO, salaries set at $475k & $450k.

AI Summary

Structure Therapeutics Inc. announced on September 12, 2024, the appointment of Dr. Jian-Hua Xu as Chief Medical Officer and Dr. Xiaojun Tang as Chief Development Officer. The company also disclosed that Dr. Xu will receive an annual base salary of $475,000, and Dr. Tang will receive an annual base salary of $450,000, both effective September 12, 2024. These appointments are part of the company's ongoing efforts to advance its drug development pipeline.

Why It Matters

The appointment of experienced executives in key medical and development roles signals Structure Therapeutics' commitment to advancing its drug pipeline, potentially impacting the company's future growth and product success.

Risk Assessment

Risk Level: low — The filing primarily concerns executive appointments and compensation, which are standard corporate events and do not inherently present significant new risks.

Key Numbers

• $475,000 — CMO Salary (Annual base salary for new Chief Medical Officer, Dr. Jian-Hua Xu.)
• $450,000 — CDO Salary (Annual base salary for new Chief Development Officer, Dr. Xiaojun Tang.)

Key Players & Entities

• Structure Therapeutics Inc. (company) — Filing company
• Dr. Jian-Hua Xu (person) — Appointed Chief Medical Officer
• Dr. Xiaojun Tang (person) — Appointed Chief Development Officer
• $475,000 (dollar_amount) — Annual base salary for Dr. Jian-Hua Xu
• $450,000 (dollar_amount) — Annual base salary for Dr. Xiaojun Tang
• September 12, 2024 (date) — Effective date of appointments and compensation

FAQ

Key Financial Figures

• $0.0001 — enting three ordinary shares, par value $0.0001 per ordinary share GPCR Nasdaq Glo
• $16,000 — receive (i) advisory fees at a rate of $16,000 per month provided he spends up to thir

Filing Documents

• tm2424160d1_8k.htm (8-K) — 42KB
• tm2424160d1_ex99-1.htm (EX-99.1) — 13KB
• tm2424160d1_img001.jpg (GRAPHIC) — 16KB
• 0001104659-24-100668.txt ( ) — 306KB
• gpcr-20240912.xsd (EX-101.SCH) — 4KB
• gpcr-20240912_def.xml (EX-101.DEF) — 27KB
• gpcr-20240912_lab.xml (EX-101.LAB) — 36KB
• gpcr-20240912_pre.xml (EX-101.PRE) — 25KB
• tm2424160d1_8k_htm.xml (XML) — 6KB

02 Departure

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Medical Officer On September 12, 2024, Mark Bach, M.D., Ph.D. entered into a separation and consulting agreement (the "Bach Separation and Consulting Agreement") with Structure Therapeutics Inc. (the "Company") in connection with his departure as Chief Medical Officer ("CMO") as part of a planned succession, effective as of September 18, 2024 (the "Effective Date"). Following the Effective Date, Dr. Bach will remain as an employee of the Company until September 23, 2024 (the "Separation Date"). To ensure an orderly transition, Dr. Bach has agreed to serve in an advisory capacity to the Company through December 31, 2024, which period may be further extended with the mutual written agreement of Dr. Bach and the Company (the "Advisory Period"). Pursuant to the Bach Separation and Consulting Agreement, Dr. Bach will be entitled to receive, subject to Dr. Bach's timely execution of a customary release of claims in favor of the Company and compliance with his obligations under the Bach Separation and Consulting Agreement: (a) a lump sum amount equal to nine months of his then-current annual base salary; (b) COBRA group health insurance continuation ending nine months after the Separation Date; and (c) acceleration of vesting of unvested time-based equity awards as if he had provided an additional six months of continued services following the Separation Date. As compensation for advisory services performed under the Bach Separation and Consulting Agreement, Dr. Bach will be eligible to receive (i) advisory fees at a rate of $16,000 per month provided he spends up to thirty-two hours per month providing advisory services during the Advisory Period; and (ii) a lump sum amount to be determined by the Company at the end of the Advisory Period, based upon the Company's achievement of certain corpora

01 Regulation

Item 7.01 Regulation FD Disclosure. On September 17, 2024, the Company issued a press release announcing Dr. Bach's departure and Dr. Coll's and Ms. Hall's appointments. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information set forth in this Item 7.01 and in the press release attached hereto as Exhibit 99.1, is deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent that the Company specifically incorporates it by reference.

01 Other

Item 8.01 Other Events. Appointment of Chief Medical Officer On September 17, 2024, the Company announced the appointment of Blai Coll, M.D., Ph.D., as the Company's CMO as part of the planned succession replacing Dr. Bach, effective as of the Effective Date. Dr. Coll, 51, most recently served as the Company's Vice President of Endocrine and Metabolism Clinical Development beginning in May 2022. Prior to joining the Company, Dr. Coll served in various roles at Amgen Inc. ("Amgen") from August 2016 to May 2022, including as Cardiovascular and Metabolic Platform Lead, Medical Affairs from June 2020 to May 2022, and Medical Lead for Repatha from November 2018 to June 2020, leading lifecyle management of Repatha including late-stage clinical studies and extension studies in more than 6,000 patients. Before joining Amgen, Dr. Coll served as Medical Director at AbbVie Inc., leading the late-stage atrasentan clinical program for chronic kidney disease, including a Phase 3 multinational outcomes study. Dr. Coll earned his medical degree from Universitat Autonoma de Barcelona School of Medicine and a Ph.D. from Universitat Rovira i Virgili. Appointment of Chief Development Officer On September 17, 2024, the Company announced the appointment of Ashley Hall, J.D., as the Company's Chief Development Officer, effective as of the Effective Date. Ms. Hall, 52, most recently served as Chief Development Officer of Reneo Pharmaceuticals beginning in October 2021. Prior to joining Reneo Pharmaceuticals, Ms. Hall was the Chief Development Officer of Esperion Therapeutics, Inc., a public pharmaceutical company, from August 2019 to August 2021. Prior to that, she served as Esperion's Senior Vice President of Global Regulatory Affairs and Policy from January 2018 to August 2019 and as its Vice President of Global Regulatory Affairs and Policy from August 2015 to January 2018. In those roles, she was responsible for the conduct of five pivotal low density lipoprotein cholesterol (

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated September 17, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Structure Therapeutics Inc. Date: September 17, 2024 By: /s/ Raymond Stevens Raymond Stevens, Ph.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR